In ₹ Crore except Per Share Latest Annual	ENTERO FY26	MEDPLUS FY26	EMIL FY26	CRIZAC FY26	Peer Average
Valuation — at last close
P/E	58.98×	32.63×	57.36×	◆ 11.46×	33.81× +74%
P/B	4.02×	◆ 3.63×	3.77×	4.30×	3.90× +3%
EV/EBITDA	26.79×	11.06×	15.92×	◆ 8.24×	11.74× +128%
Market Cap	₹6,785 Cr	₹7,180 Cr	₹6,135 Cr	₹2,511 Cr	₹5,275 Cr +29%
Growth
Revenue CAGR 3Y	—	◆ 14.78%	9.67%	—	12.22%
Revenue CAGR 5Y	—	17.56%	—	—	17.56%
Net Income CAGR 3Y	—	◆ 63.65%	-4.45%	—	29.60%
Revenue YoY (latest Q)	38.23%	21.30%	◆ 39.07%	-36.72%	7.88% +385%
Net Income YoY (latest Q)	72.17%	1.02%	◆ 458.07%	-25.04%	144.68% -50%
Profitability
EBITDA Margin	4.03%	8.81%	6.10%	◆ 27.41%	14.11% -71%
Net Income Margin	2.21%	3.19%	1.49%	◆ 21.03%	8.57% -74%
Return on Common Equity	6.74%	11.82%	6.79%	◆ 37.48%	18.70% -64%
Return on Capital Employed	11.51%	10.77%	10.17%	◆ 42.88%	21.27% -46%
Return on Assets	4.63%	6.02%	2.86%	◆ 25.03%	11.30% -59%
Credit & Quality
Total Debt/Equity	0.32×	◆ 0.00×	0.55×	0.00×	0.18× +75%
Interest Coverage	4.09×	2.69×	1.84×	◆ 3925.86×	1310.13× -100%
Scale — latest FY
Revenue / Total Income	₹6,591 Cr	₹6,892 Cr	₹7,183 Cr	₹1,042 Cr	₹5,039 Cr +31%
Net Income	₹146 Cr	₹220 Cr	₹107 Cr	₹219 Cr	₹182 Cr -20%
Total Assets	₹3,600 Cr	₹3,933 Cr	₹3,797 Cr	₹876 Cr	₹2,868 Cr +26%
EPS	₹26.44	₹18.33	₹2.78	₹12.52	₹11.21 +136%
Book Value per Share	₹388.09	₹164.54	₹42.26	₹33.41	₹80.07 +385%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.